Staphylococcal Infections Clinical Trial
Official title:
Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)
Verified date | May 2012 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | Japan: Pharmaceuticals and Medical Devices Agency (PMDA) |
Study type | Observational |
Drug use investigation of Zyvox for patients with Methicillin-resistant Staphylococcus
aureus (MRSA) infection disease.
The objective of this surveillance is to collect information about 1) adverse drug reaction
not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of
adverse drug reactions in this surveillance, and 3)factors considered to affect the safety
and/or efficacy of this drug.
Status | Completed |
Enrollment | 1004 |
Est. completion date | April 2011 |
Est. primary completion date | April 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Patients need to be administered Linezolid in order to be enrolled in the surveillance. Exclusion Criteria: - Patients not administered Linezolid. |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Adverse Drug Reaction Not Expected From the Japanese Package Insert. | The adverse drug reaction that have not been listed in Japanese package insert. | Baseline to 8 weeks | Yes |
Primary | Number of Participants With Adverse Drug Reactions(ADRs). | All observed or volunteered adverse events and the investigator's opinion of the causal relationship to the study treatment were reported. Adverse Drug Reactions were evaluated in company with the causal relationship to the investigational product. | 8 weeks | Yes |
Primary | Factors Considered to Affect the Safety of Linezolid - Gender. | Number of participants with adverse drug reaction to determine whether male or female is significant risk factor. | 8 weeks | Yes |
Primary | Factors Considered to Affect the Safety of Linezolid - Age | Number of participants with adverse drug reaction to determine whether over 65 or less than 65 is significant risk factor. | 8 weeks | Yes |
Primary | Factors Considered to Affect the Safety of Linezolid - Hepatic Dysfunctions. | Number of participants with or without Hepatic dysfunctions with adverse drug reaction to determine whether with or without is significant risk factor. | 8 weeks | Yes |
Primary | Factors Considered to Affect the Safety of Linezolid - Renal Dysfunctions. | Number of participants with or without Renal dysfunctions with adverse drug reaction to determine whether with or without is significant risk factor. | 8 weeks | Yes |
Primary | Factors Considered to Affect the Safety of Linezolid - Duration of Drug Administration. | Number of participants with Duration of drug administration as over 15 days or less than 15 days with adverse drug reaction to determine whether over 15 days or less than 15 days is significant risk factor. | 8 weeks | Yes |
Primary | Factors Considered to Affect the Safety of Linezolid - Route of Administration. | Number of participants Route of administration as by oral,injection or oral from injection with adverse drug reaction to determine whether oral, injection or switch is significant risk factor. | 8 weeks | Yes |
Primary | Factors Considered to Affect the Safety of Linezolid - Weight. | Number of participants Weight as over 40kg or less than 40kg with adverse drug reaction to determine whether over 40kg or less than 40kg Weight is significant risk factor. | 8 weeks | Yes |
Primary | Factors Considered to Affect the Safety of Linezolid - Concomitant Drugs. | Number of participants with or without Concomitant drugs with adverse drug reaction to determine whether with or without is significant risk factor. | 8 weeks | Yes |
Primary | Factors Considered to Affect the Safety of Linezolid - Non-drug Therapies. | Number of participants with or without Non-drug therapies with adverse drug reaction to determine whether with or without is significant risk factor. | 8 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01447407 -
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
|
Phase 1 | |
Recruiting |
NCT00518076 -
Staphylococcus Aureus Carriers Students Nursing Oxacillin Resistant
|
N/A | |
Completed |
NCT01324440 -
Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)
|
Phase 1 | |
Completed |
NCT00501150 -
Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections
|
N/A | |
Completed |
NCT00071214 -
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
|
Phase 3 | |
Completed |
NCT00063089 -
Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever
|
Phase 1/Phase 2 | |
Completed |
NCT00175370 -
Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus
|
N/A | |
Recruiting |
NCT03456544 -
Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
|
||
Completed |
NCT02557568 -
Evaluation of an Algorithm for Identifying Persistent Nasal Staphylococcus Aureus Carriage in a Cohort of Healthy Volunteers and Patients Regularly Monitored at the CHU of Saint-Etienne
|
N/A | |
Terminated |
NCT01196169 -
Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty
|
Phase 4 | |
Completed |
NCT02971657 -
Bacterial Phenotype of Staphylococcus Aureus Has no Effect on Patients` Clinical Outcome in Orthopedic Device Related Bone Infections
|
N/A | |
Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
Completed |
NCT02640937 -
Biofilm Formation in Staphylococcus Epidermidis Associated Implant Infections
|
N/A | |
Completed |
NCT00303069 -
V710 First-In-Man (FIM) Study (V710-001)
|
Phase 1 | |
Completed |
NCT00156377 -
Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections
|
Phase 4 | |
Completed |
NCT00631566 -
Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons
|
N/A | |
Completed |
NCT00113191 -
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
|
N/A | |
Completed |
NCT02782078 -
Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections
|
N/A | |
Completed |
NCT00859677 -
Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
|
||
Completed |
NCT00211900 -
Evaluation of Manufacturing Lot of StaphVAX
|
Phase 3 |